[¹⁸F]PSMA-1007
Ligand of imaging of PSMA expression in vivo

• Localisation of lesions of prostate cancer

[¹⁸F]Flumazenil
Imaging of GABA(A) receptors in vivo

• Presurgical evaluation of temporal lobe epilepsy
• Imaging the ischemic penumbra and assessment of therapeutic response

[¹⁸F]Fallypride
Imaging of D2/D3 receptors in vivo

• Differential diagnosis of idiopathic parkinsonian syndrome (IPS, Parkinson’s disease) and atypical parkinsonian syndrome (APS)
• Dose-finding PET occupancy studies of novel antipsychotics

[¹⁸F]FES
[¹⁸F]Fluoroestradiol
Imaging of estrogen receptors in vivo

• Predictive imaging of response to endocrine therapy in women with oestrogen receptor positive breast cancer
• Detection of lesions of breast cancer when antioestrogene treatment is a therapeutic option

[¹⁸F]Mefway
Imaging of 5-HT1A receptors in vivo

• Imaging of 5-HT1A receptors in anxiety disorders and depression
• Drug development: Occupancy of agonist drugs at the 5-HT1A receptor

[⁶⁸Ga]PSMA-11
Ligand of imaging of PSMA expression in vivo

• Localisation of lesions of prostate cancer

[⁶⁸Ga]DOTA-NOC
[⁶⁸Ga]DOTA-1-Nal3-octreotide
Imaging of somatostatin receptors in vivo

• Characterisation, localisation, staging and restating of gastroenteropancreatic neuroendocrine tumours
• Detection of the primary occult neuroendocrine tumor when a metastasis of primary neuroendocrine tumor has been demonstrated or when the serum concentration of specific marker is increased